{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T17:15:23Z","timestamp":1720372523027},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1097\/fpc.0000000000000373","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T20:52:52Z","timestamp":1553028772000},"page":"106-113","source":"Crossref","is-referenced-by-count":5,"title":["N-acetyltransferase 2 enzyme genotype\u2013phenotype discordances in both HIV-negative and HIV-positive Nigerians"],"prefix":"10.1097","volume":"29","author":[{"given":"Olayinka A.","family":"Kotila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olufunmilayo I.","family":"Fawole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olufunmilayo I.","family":"Olopade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adejumoke I.","family":"Ayede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeyinka G.","family":"Falusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinedum P.","family":"Babalola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210213","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2125.2010.03784.x","article-title":"Hypersensitivity reactions to HIV therapy","volume":"71","author":"Chaponda","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"R2-2-20210213","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00008571-200011000-00005","article-title":"Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity","volume":"10","author":"Pirmohamed","year":"2000","journal-title":"Pharmacogenetics"},{"key":"R3-2-20210213","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/FPC.0000000000000062","article-title":"PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2","volume":"24","author":"McDonagh","year":"2014","journal-title":"Pharmacogenet Genomics"},{"key":"R4-2-20210213","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/bmj.316.7140.1295","article-title":"Adverse drug reactions","volume":"316","author":"Pirmohamed","year":"1998","journal-title":"Br Med J (International Ed"},{"key":"R5-2-20210213","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2125.2003.01754.x","article-title":"Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity","volume":"55","author":"Alfirevic","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"R6-2-20210213","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/00007611-200194080-00014","article-title":"Practical issues in the management of hypersensitivity reactions: sulfonamides","volume":"94","author":"Tilles","year":"2001","journal-title":"South Med J"},{"key":"R7-2-20210213","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/0003-4819-105-2-179","article-title":"Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity","volume":"105","author":"Shear","year":"1986","journal-title":"Ann Intern Med"},{"key":"R8-2-20210213","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/jac\/37.suppl_B.55","article-title":"Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis","volume":"37","author":"Van der Ven","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"R9-2-20210213","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2125.2010.03764.x","article-title":"Delayed drug hypersensitivity: models of T-cell stimulation","volume":"71","author":"Adam","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"R10-2-20210213","doi-asserted-by":"crossref","first-page":"268","DOI":"10.4065\/84.3.268","article-title":"Mechanisms of drug-induced allergy","volume":"84","author":"Schnyder","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"R11-2-20210213","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1939-4551-6-18","article-title":"Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy","volume":"6","author":"S\u00e1nchez-Borges","year":"2013","journal-title":"World Allergy Organ J"},{"key":"R12-2-20210213","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/00970002042006004","article-title":"Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity","volume":"42","author":"O\u2019Neil","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R13-2-20210213","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00008571-200003000-00009","article-title":"Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype","volume":"10","author":"O\u2019Neill","year":"2000","journal-title":"Pharmacogenetics"},{"key":"R15-2-20210213","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12916-016-0593-7","article-title":"Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy","volume":"14","author":"Crook","year":"2016","journal-title":"BMC Med"},{"key":"R16-2-20210213","doi-asserted-by":"crossref","first-page":"404","DOI":"10.4103\/0300-1652.171611","article-title":"Self-reported sulphonamide hypersensitivity reactions in adults living in Ibadan, Nigeria: a cross-sectional, community-based study","volume":"56","author":"Akpan","year":"2015","journal-title":"Niger Med J"},{"key":"R17-2-20210213","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","article-title":"Haploview: analysis and visualization of LD and haplotype maps","volume":"21","author":"Barrett","year":"2005","journal-title":"Bioinformatics"},{"key":"R18-2-20210213","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2350-10-148","article-title":"Evaluating NAT2PRED for inferring the individual acetylation status from unphased genotype data","volume":"10","author":"Sabbagh","year":"2009","journal-title":"BMC Med Genet"},{"key":"R19-2-20210213","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/bioinformatics\/btp121","article-title":"NAT2PRED: a web-server for inferring the acetylator phenotype of the human N-acetyltransferase-2 (NAT2) from NAT2 genotype","volume":"25","author":"Kuznetsov","year":"2009","journal-title":"Bioinformatics"},{"key":"R20-2-20210213","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/2050-6511-15-32","article-title":"Self-reported adverse drug reactions and their influence on highly active antiretroviral therapy in HIV infected patients: a cross sectional study","volume":"15","author":"Wondmagegn Tamiru","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"R21-2-20210213","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1398-9995.1999.tb04745.x","article-title":"Diagnosis of allergic reactions to sulfonamides","volume":"54","author":"Gruchalla","year":"1999","journal-title":"Allergy"},{"key":"R22-2-20210213","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.puhe.2004.07.013","article-title":"Self-reported food and drug allergy in Maputo, Mozambique","volume":"119","author":"Lunet","year":"2005","journal-title":"Public Health"},{"key":"R23-2-20210213","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10389-012-0496-9","article-title":"Prevalence of hypersensitivity reactions against drugs among adult population in Turkey: a self-reported survey","volume":"20","author":"Bavbek","year":"2012","journal-title":"J Public Health"},{"key":"R24-2-20210213","first-page":"31","article-title":"Immediate-type drug hypersensitivity and associated factors in a general population.","volume":"27-","author":"Kurt","year":"39","journal-title":"Allergol Immunopathol (Madr)"},{"key":"R25-2-20210213","doi-asserted-by":"crossref","first-page":"e73166","DOI":"10.1371\/journal.pone.0073166","article-title":"Prevalence and perceived preventability of self-reported adverse drug events \u2013 a population-based survey of 7099 adults","volume":"8","author":"Hakkarainen","year":"2013","journal-title":"PLoS ONE"},{"key":"R26-2-20210213","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/j.1365-2222.2004.02070.x","article-title":"Self-reported drug allergy in a general adult Portuguese population","volume":"34","author":"Gomes","year":"2004","journal-title":"Clin Exp Allergy"},{"key":"R27-2-20210213","doi-asserted-by":"crossref","first-page":"125301","DOI":"10.1016\/j.amjmed.2009.01.034","article-title":"Self-reported antibiotic allergy incidence and prevalence: age and sex effects","volume":"122","author":"Macy","year":"2009","journal-title":"Am J Med"},{"key":"R28-2-20210213","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1590\/S1807-59322010001000014","article-title":"Drug hypersensitivity in students from S\u00e3o Paulo, Brazil","volume":"65","author":"Ensina","year":"2010","journal-title":"Clinics (Sao Paulo"},{"key":"R29-2-20210213","first-page":"1269","article-title":"Advances in brief age-associated risk of cancer among individuals with N-acetyltransferase 2 (NAT2) mutations and mutations in DNA mismatch repair genes 1","volume":"61","author":"Frazier","year":"2001","journal-title":"Cancer Res"},{"key":"R30-2-20210213","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.1994.tb04401.x","article-title":"N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients","volume":"38","author":"Delomenie","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"R31-2-20210213","first-page":"1","article-title":"Racial and ethnic differences in response to medicines: towards individualised pharmaceutical treatment","volume":"94","author":"Burroughs","year":"2002","journal-title":"J Natl Med Assoc"},{"key":"R32-2-20210213","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4000\/bmsap.5223","article-title":"Haplotype tagging efficiency and tagSNP sets portability in worldwide populations in NAT2 gene","volume":"19","author":"Sabbagh","year":"2007","journal-title":"Bull Mem Soc Anthropol Paris"},{"key":"R33-2-20210213","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00008571-199902000-00016","article-title":"Pitfalls in N-acetyltransferase 2 genotyping","volume":"9","author":"Cascorbi","year":"1999","journal-title":"Pharmacogenetics"},{"key":"R34-2-20210213","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1158\/1055-9965.1543.13.9","article-title":"Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer","volume":"13","author":"Deitz","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R35-2-20210213","first-page":"1","article-title":"Arylamine N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms\u2019 frequencies in Nigerian populations","volume":"1","author":"Ebeshi","year":"2011","journal-title":"Afr J Pharm Pharmacol Res"},{"key":"R36-2-20210213","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/01.fpc.0000173485.59430.49","article-title":"Association of N-acetyl transferase 2 gene polymorphism and slow acetylator phenotype with young onset and late onset Parkinson\u2019s disease among Indians","volume":"15","author":"Chaudhary","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"R37-2-20210213","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s00204-015-1635-1","article-title":"The ultra-slow NAT2*6A haplotype is associated with reduced higher cognitive functions in an elderly study group","volume":"89","author":"Selinski","year":"2015","journal-title":"Arch Toxicol"},{"key":"R38-2-20210213","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.3748\/wjg.v13.45.6003","article-title":"NAT2*6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-inducedhepatotoxicity in Japanese patients with tuberculosis","volume":"13","author":"Higuchi","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R39-2-20210213","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2156-9-21","article-title":"Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history","volume":"9","author":"Sabbagh","year":"2008","journal-title":"BMC Genet"},{"key":"R40-2-20210213","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2217\/pgs.11.122","article-title":"Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes","volume":"13","author":"Hein","year":"2012","journal-title":"Pharmacogenomics"},{"key":"R41-2-20210213","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/0091270006288955","article-title":"Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects","volume":"46","author":"Straka","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"R42-2-20210213","first-page":"475","article-title":"Variability in drug metabolising enzyme activity in HIV-infected patients","volume":"66","author":"Jones","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"R43-2-20210213","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/FPC.0b013e328357a735","article-title":"Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity","volume":"22","author":"Sacco","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R44-2-20210213","first-page":"875","article-title":"Genotype and phenotype of NAT2 and the occurrence of adverse drug reactions in Mexican individuals to an isoniazid-based prophylactic chemotherapy for tuberculosis","volume":"1","author":"D\u00edaz-Molina","year":"2008","journal-title":"Mol Med Rep"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:29:01Z","timestamp":1663115341000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201907000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000373","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}